ResMed Inc. DEF 14A: Executive Compensation Details

Ticker: RSMDF · Form: DEF 14A · Filed: Oct 3, 2024 · CIK: 943819

Resmed Inc DEF 14A Filing Summary
FieldDetail
CompanyResmed Inc (RSMDF)
Form TypeDEF 14A
Filed DateOct 3, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$4.7B, $30B, $30 billion, $1.4 billion, $1.3 billion
Sentimentneutral

Sentiment: neutral

Topics: executive-compensation, proxy-statement, annual-filing

TL;DR

ResMed's 10-K shows exec pay details, equity awards for FY24 are in.

AI Summary

ResMed Inc. filed its DEF 14A on October 3, 2024, for the fiscal year ending June 30, 2024. The filing details executive compensation, including equity awards granted and outstanding, for the fiscal years 2020 through 2024. Specific figures for the value of equity awards granted and outstanding are provided for key personnel.

Why It Matters

This filing provides transparency into how ResMed Inc. compensates its top executives, which can influence investor perception and corporate governance.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) detailing executive compensation and corporate governance, not indicating new or unusual risks.

Key Numbers

  • 20240630 — Fiscal Year End (Reporting period for the filing.)
  • 20241003 — Filing Date (Date the DEF 14A was submitted to the SEC.)

Key Players & Entities

  • RESMED INC (company) — Filer
  • 9001 SPECTRUM CENTER BLVD. (location) — Business Address
  • SAN DIEGO (location) — Business Address City
  • CA (location) — Business Address State
  • 92123 (location) — Business Address Zip

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, such as the election of directors and executive compensation.

What fiscal period does this DEF 14A filing cover?

This DEF 14A filing by ResMed Inc. covers the fiscal year ending on June 30, 2024.

Where is ResMed Inc. headquartered?

ResMed Inc.'s business and mailing address is listed as 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA 92123.

What industry does ResMed Inc. operate in?

ResMed Inc. operates in the 'SURGICAL & MEDICAL INSTRUMENTS & APPARATUS' industry, with SIC code 3841.

What specific financial data related to compensation is detailed in this filing?

The filing includes details on equity awards granted, outstanding equity awards, and changes in the value of equity awards for ResMed Inc. executives over several fiscal years, including 2020-2024.

Filing Stats: 4,388 words · 18 min read · ~15 pages · Grade level 17 · Accepted 2024-10-03 12:35:42

Key Financial Figures

  • $4.7B — Diego, CA Founded 1989 FY2024 revenue $4.7B Listed (NYSE, ASX) 1995, RMD Market
  • $30B — sted (NYSE, ASX) 1995, RMD Market cap ~$30B Countries served 140+ Total employee
  • $30 billion — 4 GAAP l 2024 Non-GAAP Market cap of $30 billion as of 8/1/2024 140 countries served G
  • $1.4 billion — ies served GAAP operating cash flow of $1.4 billion Free cash flow* of $1.3 billion $3 bi
  • $1.3 billion — low of $1.4 billion Free cash flow* of $1.3 billion $3 billion in capital deployed over th
  • $3 billion — llion Free cash flow* of $1.3 billion $3 billion in capital deployed over the last three
  • $218.50 — a result, our stock price, which was at $218.50 at June 30, 2023, and $148.90 on the No
  • $148.90 — ch was at $218.50 at June 30, 2023, and $148.90 on the November 23rd annual equity awar
  • $191.42 — l equity award grant date, recovered to $191.42 at fiscal year end of June 30, 2024 and
  • $247.15 — nd of June 30, 2024 and has improved to $247.15 as of the record date. The table belo
  • $0.48 — we maintained the quarterly dividend of $0.48 per share paid to our stockholders, pay
  • $282 million — our stockholders, paying approximately $282 million to our stockholders in dividends, repre
  • $0.53 — terly dividend by approximately 10%, to $0.53 per share for fiscal year 2025. We also
  • $150 million — year 2024 we repurchased approximately $150 million of stock, more than offsetting the dilu

Filing Documents

Executive Compensation

Executive Compensation 45 Proposal 3 Advisory Vote to Approve Named Executive Officer Compensation 45 Introduction 46 Compensation Discussion and Analysis (CD&A) 47 Compensation Committee Report 66

Executive Compensation Tables

Executive Compensation Tables 67 Chief Executive Officer Pay Ratio 79 Pay versus Performance 80 Stock Ownership Information 84 Common Stock Ownership of Principal Stockholders and Management 84 Delinquent Section 16(a) Reporting 85 Equity Compensation Plan Information 86 Stockholder Proposals for 2025 Annual Meeting 87 Voting Instructions and General Information 89 Cautionary Note Regarding Forward-Looking Statements 95 No Incorporation by Reference 96 Reconciliation of Non-GAAP Financial Measures 97 Certain statements in this proxy statement, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives and expected operating results, and the assumptions upon which those statements are based, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may appear throughout this report. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward- looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. We undertake no obligation to update or revise publicly any forward- looking statements, whether as a result of new information, future events, or otherwise. 2024 Proxy Statement | 3 Table of Contents About ResMed Founded in 1989, and headquartered in San Diego, California, USA, ResMed pioneers innovative solutions that treat and keep people suffering from respiratory conditions out of the hospital, empowerin

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.